ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['cilta-cel', 'cartitude-4', 'cartitude']
further cartitude-4 efficacy data
- subgroup analysis shows uniform benefit
- unsurprisingly pts receiving cilta-cel as earlier line did better
- improved depth of responses with cilta-cel / higher rates of mrd-negativitiy
- no os curve which makes pfs hard to interpret #asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem